DEVELOPMENT AND VALIDATION OF RP HPLC METHOD FOR THE ESTIMATION OF ETORICOXIB IN BULK AND TABLETS

Objective: Objective of the present analytical research work was to develop and validate Reverse Phase High Performance Liquid Chromatographic method (RP-HPLC Method) for the Etoricoxib in bulk and tablets dosage form.Methods: A RP-HPLC method has been developed and validated for estimation of ETOR in pharmaceutical oral dosage form.Method A (RP-HPLC Method): The RP-HPLC Method for Etoricoxib was developed using Shimadzu HPLC, LC-10, temperature maintained 25 0 C, phenorex Gemini C18 (250 mm × 4.60 mm × 5μm), as stationary particle, isocratic mode.Water: ACN: OPA: TEA (40:60:0.1:0.1, v/vv/v).Mobile phase was maintained at a flow rate of 1.0 ml/min and detection was carried out at 245 nm.Results: Etoricoxib was found to be linear in the concentration range of 8 -12 μg/ml for RP-HPLC method.Retention time was found to be 2.7 min for Etoricoxib.The amount of Etoricoxib in marketed formulation was found to be 99.33 %. Interpretation and Conclusion:Results of assay and validation study were found to be satisfactory.So, the method can be successfully applied for the routine analysis of Etoricoxib.